Leaving behind pegylated interferon-based regimens to eliminate hepatitis C as a public health threat by 2030 as set out by WHO
Liver Int
.
2018 Nov;38(11):1902-1905.
doi: 10.1111/liv.13944.
Authors
Jeffrey V Lazarus
1
,
Juan M Pericàs
1
,
Ahmed M Elsharkawy
2
Affiliations
1
Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
2
Liver Unit, University Hospitals Birmingham, Birmingham, UK.
PMID:
30358061
DOI:
10.1111/liv.13944
No abstract available
Publication types
Editorial
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Antiviral Agents*
Hepatitis C, Chronic*
Hong Kong
Humans
Interferons
Public Health
Substances
Antiviral Agents
Interferons